Quick Answer
NeuroPace Inc reported Research And Development Expense of $27.89 million for the year ending 2025.
- NeuroPace Inc showed an increase of +17.9% in Research And Development Expense from 2024 to 2025.
- This data is from NeuroPace Inc's annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $4.83 million | Q2 2020: $3.25 million | Q3 2020: $3.69 million | Q1 2021: $4.10 million | Q2 2021: $4.44 million | Q3 2021: $4.33 million | Q1 2022: $5.58 million | Q2 2022: $5.67 million | Q3 2022: $5.61 million | Q1 2023: $5.26 million | Q2 2023: $5.34 million | Q3 2023: $4.80 million | Q1 2024: $5.78 million | Q2 2024: $6.07 million | Q3 2024: $5.75 million | Q1 2025: $7.44 million | Q2 2025: $6.85 million | Q3 2025: $6.58 million.
- Over the full 6 years of available data (2020 to 2025), NeuroPace Inc's Research And Development Expense has grown by 77.7%.
- Historical annual values: Fiscal year 2025: $27.89 million | Fiscal year 2024: $23.65 million | Fiscal year 2023: $20.78 million | Fiscal year 2022: $21.95 million | Fiscal year 2021: $18.21 million | Fiscal year 2020: $15.70 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: